Prospective study of the real impact of fusion centered genomic assays in patient management in a national collaborative group: the GETHI-XX-16 study.
Advanced cancer
Fusion
Mutation
NGS
Precision medicine
Journal
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
ISSN: 1699-3055
Titre abrégé: Clin Transl Oncol
Pays: Italy
ID NLM: 101247119
Informations de publication
Date de publication:
01 Nov 2024
01 Nov 2024
Historique:
received:
24
07
2024
accepted:
21
09
2024
medline:
1
11
2024
pubmed:
1
11
2024
entrez:
1
11
2024
Statut:
aheadofprint
Résumé
Precision medicine represents a paradigm shift in oncology. Access to genetic testing and targeted therapies is frequently limited. Assays based on DNA sequencing can miss druggable alterations. We aimed to determine the impact of a free access program to RNA tests in patient management. We designed a multicenter prospective observational study within the Spanish National Group for Translational Oncology and Rare and Orphan Tumors (GETTHI). Eligible patients were adults with solid cancers that had progressed on standard therapies. Tumor samples were analyzed using two RNA sequencing assays (Trailblaze Pharos Between November 2016 and April 2019, 395 patients with 41 different tumors across 30 hospitals were included. Molecular analysis revealed actionable genetic alterations in 57 individuals (14.4%). Targeted therapies were advised for 23 and seven received a matched targeted therapy: two lung cancers (EML4-ALK and CD74-ROS1 fusion), three glioblastomas (EGFR point mutations), one oligodendroglioma (FGFR3-TACC3 fusion) and a prostate cancer (SND1-BRAF fusion). The outcomes included two tumor responses, one disease stabilization, one early withdrawal due to toxicity, one progression, and one unknown. Despite the growing knowledge of cancer biology and its translation to drug development, the overall impact of personalized treatments remains low. Access to comprehensive molecular tests covering properly all known actionable alterations and programs for a wide access to targeted therapies seem to be critical steps.
Identifiants
pubmed: 39485597
doi: 10.1007/s12094-024-03745-5
pii: 10.1007/s12094-024-03745-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).
Références
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics. CA Cancer J Clin. 2023;73(1):17–48.
doi: 10.3322/caac.21763
pubmed: 36633525
Mardis ER. The impact of next-generation sequencing on cancer genomics: from discovery to clinic. Cold Spring Harb Perspect Biol. 2019;11(9):1–14.
Chen H, Li J, Wang Y, Ng PKS, Tsang YH, Shaw KR, et al. Comprehensive assessment of computational algorithms in predicting cancer driver mutations. Genome Biol. 2020;21(1):43. https://doi.org/10.1186/s13059-020-01954-z .
doi: 10.1186/s13059-020-01954-z
pubmed: 32079540
pmcid: 7033911
Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, et al. Comprehensive characterization of cancer driver genes and mutations. Cell. 2018;173(2):371-385.e18.
doi: 10.1016/j.cell.2018.02.060
pubmed: 29625053
pmcid: 6029450
DeMatteo RP, Ballman K V, Antonescu CR, Maki RG, Pisters PW, Demetri GD, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet [Internet]. 2009 Mar; 373(9669):1097–104. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673609605006
Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107–14. https://doi.org/10.1056/NEJMoa1203421 .
doi: 10.1056/NEJMoa1203421
pubmed: 22663011
Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, et al. First-line lorlatinib or crizotinib in advanced ALK -positive lung cancer. N Engl J Med. 2020;383(21):2018–29. https://doi.org/10.1056/NEJMoa2027187 .
doi: 10.1056/NEJMoa2027187
pubmed: 33207094
Mateo L, Duran-Frigola M, Gris-Oliver A, Palafox M, Scaltriti M, Razavi P, et al. Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns. Genome Med. 2020;12(1):1–23.
doi: 10.1186/s13073-020-00774-x
Zheng Z, Liebers M, Zhelyazkova B, Cao Y, Panditi D, Lynch KD, et al. Anchored multiplex PCR for targeted next-generation sequencing. Nat Med. 2014;20(12):1479–84. https://doi.org/10.1038/nm.3729 .
doi: 10.1038/nm.3729
pubmed: 25384085
Kresse SH, Namløs HM, Lorenz S, Berner JM, Myklebost O, Bjerkehagen B, et al. Evaluation of commercial DNA and RNA extraction methods for high-throughput sequencing of FFPE samples. PLoS ONE. 2018;13(5):1–12.
doi: 10.1371/journal.pone.0197456
Vendrell JA, Taviaux S, Béganton B, Godreuil S, Audran P, Grand D, et al. Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches. Sci Rep. 2017;7(1):1–11.
doi: 10.1038/s41598-017-12679-8
Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–4.
doi: 10.1158/2159-8290.CD-12-0095
pubmed: 22588877
Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013. https://doi.org/10.1126/scisignal.2004088 .
doi: 10.1126/scisignal.2004088
pubmed: 24170934
pmcid: 3969021
Shaw AT, Gandhi L, Gadgeel S, Riely GJ, Cetnar J, West H, et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: A single-group, multicentre, phase 2 trial. Lancet Oncol. 2016;17(2):234–42. https://doi.org/10.1016/S1470-2045(15)00488-X .
doi: 10.1016/S1470-2045(15)00488-X
pubmed: 26708155
Lee JC, Vivanco I, Beroukhim R, Huang JHY, Feng WL, DeBiasi RM, et al. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med. 2006;3(12):2264–73.
doi: 10.1371/journal.pmed.0030485
Chmielecki J, Hutchinson KE, Frampton GM, Chalmers ZR, Johnson A, Shi C, et al. Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes. Cancer Discov. 2014;4(12):1398–405.
doi: 10.1158/2159-8290.CD-14-0617
pubmed: 25266736
Lee NV, Lira ME, Pavlicek A, Ye J, Buckman D, Bagrodia S, et al. A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells though MAPK activation. PLoS One. 2012. https://doi.org/10.1371/journal.pone.0039653 .
doi: 10.1371/journal.pone.0039653
pubmed: 23300931
pmcid: 3534106
Jang JS, Lee A, Li J, Liyanage H, Yang Y, Guo L, et al. Common oncogene mutations and novel SND1-BRAF transcript fusion in lung adenocarcinoma from never smokers. Sci Rep. 2015;5:1–8.
doi: 10.1038/srep09755
Fenor MD, Ruiz-Llorente S, Rodríguez-Moreno JF, Caleiras E, Torrego JC, Sevillano-Fernández E, et al. MEK inhibitor sensitivity in BRAF fusion-driven prostate cancer. Clin Transl Oncol. 2022;24(12):2432–40.
doi: 10.1007/s12094-022-02916-6
pubmed: 35994225
Marchiò C, Scaltriti M, Ladanyi M, Iafrate AJ, Bibeau F, Dietel M, et al. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Ann Oncol. 2019;30(9):1417–27.
doi: 10.1093/annonc/mdz204
pubmed: 31268127
Kumar-Sinha C, Kalyana-Sundaram S, Chinnaiyan AM. Landscape of gene fusions in epithelial cancers: seq and ye shall find. Genome Med. 2015;7(1):129. https://doi.org/10.1186/s13073-015-0252-1 .
doi: 10.1186/s13073-015-0252-1
pubmed: 26684754
pmcid: 4683719
van Belzen IAEM, Cai C, van Tuil M, Badloe S, Strengman E, Janse A, et al. Systematic discovery of gene fusions in pediatric cancer by integrating RNA-seq and WGS. BMC Cancer. 2023;23(1):618. https://doi.org/10.1186/s12885-023-11054-3 .
doi: 10.1186/s12885-023-11054-3
pubmed: 37400763
pmcid: 10318758
Le Tourneau C, Delord JP, Gonçalves A, Gavoille C, Dubot C, Isambert N, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015;16(13):1324–34.
doi: 10.1016/S1470-2045(15)00188-6
pubmed: 26342236
Massard C, Michiels S, Ferté C, Le Deley MC, Lacroix L, Hollebecque A, et al. High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discov. 2017;7(6):586–95.
doi: 10.1158/2159-8290.CD-16-1396
pubmed: 28365644
Bertucci F, Gonçalves A, Guille A, Adelaïde J, Garnier S, Carbuccia N, et al. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial. Genome Med. 2021;13(1):1–20.
doi: 10.1186/s13073-021-00897-9
Tsimberidou AM, Hong DS, Ye Y, Cartwright C, Wheler JJ, Falchook GS, et al. Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): an MD Anderson Precision Medicine Study. JCO Precis Oncol. 2017;1:1–18.
doi: 10.1200/PO.17.00002
Trédan O, Wang Q, Pissaloux D, Cassier P, de la Fouchardière A, Fayette J, et al. Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial. Ann Oncol [Internet]. 2019 May;30(5):757–65. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0923753419311676
Rodon J, Soria JC, Berger R, Miller WH, Rubin E, Kugel A, et al. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat Med. 2019;25(5):751–8.
doi: 10.1038/s41591-019-0424-4
pubmed: 31011205
pmcid: 6599610
Sicklick JK, Kato S, Okamura R, Schwaederle M, Hahn ME, Williams CB, et al. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat Med. 2019. https://doi.org/10.1038/s41591-019-0407-5 .
doi: 10.1038/s41591-019-0407-5
pubmed: 31011206
pmcid: 6553618
Gambardella V, Lombardi P, Carbonell-Asins JA, Tarazona N, Cejalvo JM, González-Barrallo I, et al. Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study. Br J Cancer. 2021;125(9):1261–9. https://doi.org/10.1038/s41416-021-01502-x .
doi: 10.1038/s41416-021-01502-x
pubmed: 34493820
pmcid: 8548537
Casolino R, Beer PA, Chakravarty D, Davis MB, Malapelle U, Mazzarella L, et al. Interpreting and integrating genomic tests results in clinical cancer care: overview and practical guidance. CA Cancer J Clin. 2024. https://doi.org/10.3322/caac.21825 .
doi: 10.3322/caac.21825
pubmed: 38174605
Chiang S, Cotzia P, Hyman DM, Drilon A, Tap WD, Zhang L, et al. HHS Public Access. 2019;42(6):791–8
Hechtman JF, Benayed R, Hyman DM, Zehir A, Frosina D, Arcila ME, et al. HHS Public Access. 2018;41(11):1547–51
Rudzinski ER, Lockwood CM, Stohr BA, Vargas SO, Sheridan R, Black JO, et al. Pan-Trk immunohistochemistry identifies NTRK rearrangements in Pediatric Mesenchymal Tumors. Am J Surg Pathol. 2018;42(7):927–35.
doi: 10.1097/PAS.0000000000001062
pubmed: 29683818
Murphy DA, Ely HA, Shoemaker R, Boomer A, Culver BP, Hoskins I, et al. Detecting gene rearrangements in patient populations through a 2-Step diagnostic test comprised of rapid ihc enrichment followed by sensitive next-generation sequencing. Appl Immunohistochem Mol Morphol. 2017;25(7):513–23.
doi: 10.1097/PAI.0000000000000360
pubmed: 27028240
Overbeck TR, Reiffert A, Schmitz K, Rittmeyer A, Körber W, Hugo S, et al. NTRK gene fusions in non-small-cell lung cancer: real-world screening data of 1068 unselected patients. Cancers. 2023;15(11):2966.
doi: 10.3390/cancers15112966
pubmed: 37296928
pmcid: 10252111